Neurotech International Beheer

Beheer criteriumcontroles 3/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Peter James Griffiths

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	4.1yrs
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	2.3yrs
Gemiddelde ambtstermijn bestuur	5.6yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Peter James Griffiths's beloning veranderd ten opzichte van Neurotech International's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-AU$5m
Mar 31 2024	n/a	n/a	-AU$5m
Dec 31 2023	n/a	n/a	-AU$5m
Sep 30 2023	n/a	n/a	-AU$6m
Jun 30 2023	n/a	n/a	-AU$8m
Mar 31 2023	n/a	n/a	-AU$6m
Dec 31 2022	n/a	n/a	-AU$5m
Sep 30 2022	n/a	n/a	-AU$4m
Jun 30 2022	n/a	n/a	-AU$3m
Mar 31 2022	n/a	n/a	-AU$4m
Dec 31 2021	n/a	n/a	-AU$6m
Sep 30 2021	n/a	n/a	-AU$7m
Jun 30 2021	AU$109k	n/a	-AU$7m
Mar 31 2021	n/a	n/a	-AU$6m
Dec 31 2020	n/a	n/a	-AU$5m
Sep 30 2020	n/a	n/a	-AU$3m
Jun 30 2020	AU$327k	AU$282k	-AU$2m
Mar 31 2020	n/a	n/a	-AU$3m
Dec 31 2019	n/a	n/a	-AU$4m
Sep 30 2019	n/a	n/a	-AU$4m
Jun 30 2019	AU$316k	AU$224k	-AU$5m
Mar 31 2019	n/a	n/a	-AU$4m
Dec 31 2018	n/a	n/a	-AU$4m
Sep 30 2018	n/a	n/a	-AU$4m
Jun 30 2018	AU$106k	AU$97k	-AU$4m

Compensatie versus markt: Er zijn onvoldoende gegevens om vast te stellen of de totale vergoeding van Peter James redelijk is in vergelijking met bedrijven van vergelijkbare omvang in de Australian markt.

Compensatie versus inkomsten: De vergoeding van Peter James is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Peter James Griffiths (60 yo)

4.1yrs

Tenure

AU$109,031

Compensatie

Mr. Peter James Lawrence Griffiths, B.Sc. (Hons), has been the Chief Executive Officer of AAT Research Ltd at Neurotech International Limited since October 2020 and served as its Chief Executive Officer an...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Alexandra Andrews	Chief Operating Officer	2.2yrs	AU$36.51k	geen gegevens
Gerald Quigley	Director of Public Relations & Director	2.3yrs	AU$136.55k	0.027% A$ 18.3k
Thomas Duthy	Executive Director	2.2yrs	AU$454.40k	0.033% A$ 22.4k
Emanuela Russo	Chief Scientific Officer & Member of Scientific Advisory Board	6.1yrs	geen gegevens	geen gegevens
Carolyn Ellaway	Chief Medical Officer	less than a year	geen gegevens	geen gegevens
Peter James Griffiths	Chief Executive Officer of AAT Research Ltd	4.1yrs	AU$109.03k	geen gegevens
Erlyn Dawson	Company Secretary	5.6yrs	geen gegevens	geen gegevens
Alessandra Gauvin	Joint Company Secretary	no data	geen gegevens	geen gegevens

2.3yrs

Gemiddelde duur

Ervaren management: Het managementteam van NTI wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.3 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Gerald Quigley	Director of Public Relations & Director	2.3yrs	AU$136.55k	0.027% A$ 18.3k
Thomas Duthy	Executive Director	2.2yrs	AU$454.40k	0.033% A$ 22.4k
Emanuela Russo	Chief Scientific Officer & Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Evian Gordon	Member of Scientific Advisory Board	6.1yrs	geen gegevens	geen gegevens
Robert Johnston	Director	less than a year	AU$34.05k	0.081% A$ 55.0k
Mark Davies	Independent Non-Executive Chairman	5.6yrs	AU$61.22k	1.14% A$ 778.3k
David Cantor	Chairman of Scientific Advisory Board (Currently Dormant)	7.9yrs	AU$34.71k	geen gegevens
Tanju Surmeli	Member of Scientific Advisory Board	6.1yrs	geen gegevens	geen gegevens

5.6yrs

Gemiddelde duur

Ervaren bestuur: De raad van bestuur van NTI wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.6 jaar).

Neurotech International Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Neurotech International Limited, Annual General Meeting, Nov 20, 2024

Less than half of directors are independent

Neurotech International Limited, Annual General Meeting, Nov 15, 2023

Neurotech International Limited Announces Passing of Professor Allan Cripps AO, Non-Executive Director

Less than half of directors are independent

Neurotech International Limited, Annual General Meeting, Nov 30, 2022

Recent updates

Now 22% overvalued

Now 20% overvalued

Neurotech International Limited, Annual General Meeting, Nov 20, 2024

Full year 2024 earnings released: AU$0.006 loss per share (vs AU$0.01 loss in FY 2023)

Less than half of directors are independent

Neurotech International Limited has completed a Follow-on Equity Offering in the amount of AUD 10 million.

Neurotech International Limited has completed a Follow-on Equity Offering in the amount of AUD 10 million.

Neurotech International Limited to Report Q1, 2024 Results on Oct 27, 2023

Neurotech International Limited, Annual General Meeting, Nov 15, 2023

Full year 2023 earnings released: AU$0.01 loss per share (vs AU$0.005 loss in FY 2022)

New minor risk - Financial data availability

Neurotech International Limited to Report Q4, 2023 Results on Jul 26, 2023

First half 2023 earnings released: AU$0.48 loss per share (vs AU$0.003 loss in 1H 2022)

Neurotech International Limited Announces First Patient Treated in Phase I/II PANDAS/PANS Trial

Neurotech International Limited Announces Approval for Additional Phase I/II ASD Trial Extension

Neurotech International Limited Receives HREC Approval for Phase I/II PANDAS/PANS Clinical Trial

Neurotech International Limited to Report Q3, 2023 Results on Jan 30, 2023

Neurotech International Limited Announces Grant of FDA Pre-IND Meeting for NTI164 in ASD

Neurotech International Limited Announces Passing of Professor Allan Cripps AO, Non-Executive Director

Neurotech International Limited Announces Commencement of Patient Randomisation and First Patient Successfully Treats Under New Phase II/III NTIASD2 Clinical Trial for Children with Autism Spectrum Disorder

Less than half of directors are independent

Neurotech International Limited, Annual General Meeting, Nov 30, 2022

Neurotech International Limited, Annual General Meeting, Nov 23, 2022

Neurotech International Limited Reports Further Significant Clinical Improvement at 20 Weeks for Paediatric Autism Patients Treated with NTI164

Neurotech International Limited Announces New Phase I/II Clinical Trial in Children with PANDAS/PANS

Neurotech International Limited Provides Autism Spectrum Disorder Phase I/II Clinical Trial Update

Less than half of directors are independent

Neurotech International Limited Announces Transition of Alexandra Andrews from Chief Executive Officer to a New Position of Chief Operating Officer

Full year 2022 earnings released: AU$0.005 loss per share (vs AU$0.015 loss in FY 2021)

Neurotech International Limited Announces Currently Finalising a Pivotal Phase II/III Clinical Trial Design to be Conducted in Australia

Neurotech International ORDINARY FULLY PAID to Be Deleted from OTC Equity

Neurotech International Limited Announces Executive Changes

Neurotech International Limited Announces Results with NTI164 in Paediatric ASD

High number of new directors

Neurotech International Limited Announces Important Developments Relating to the Study Protocol Assessing NTI164 in Children with Autism Spectrum Disorder

High number of new directors

Neurotech International Limited Announces Successful Developments Relating to Safety and Tolerability of NTI164 and Key Behavioural Parameters That Impact Autism Spectrum Disorder Patients

Neurotech International Limited Appoints Alexandra Andrews as Chief Executive Officer, Effective 8 March 2022

Neurotech International Limited Announces Nti164 Clinical Program Update

Full year 2021 earnings released: AU$0.015 loss per share (vs AU$0.011 loss in FY 2020)

Neurotech International Limited Announces the Continuation of Its Pre-Clinical Program in Neuro-Inflammatory Disease Models In-Line with Research and Development Pathway

Neurotech International Limited Initiates Phase I/II Open Label Study into Autism

Neurotech International Limited has completed a Follow-on Equity Offering in the amount of AUD 2 million.

Neurotech International Limited Announces Strategic Cultivation Partnership with CannaPacific Limited

Neurotech International Limited Announces the Expansion of Its Exclusive License with Dolce Cann Global Pty Ltd

Neurotech International Limited Provides an Update on Clinical Study Program

Neurotech International Limited has completed a Follow-on Equity Offering in the amount of AUD 2.5 million.

Neurotech International Limited Announces Initiation of Clinical Product Formulation Studies

Neurotech International Limited Announces Transition of Peter Griffiths as CEO

Neurotech International Limited Commences Landmark in Vitro Trials of Unique Cannabis Strains

Full year earnings released - AU$0.011 loss per share

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Bestuursleden

Gemiddelde duur